TCM
ESPR icon

Tang Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Tang Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,850,000
Closed -$5.53M – 113
2023
Q4 		$5.53M Hold
1,850,000
– – 0.51% 49
2023
Q3 		$1.81M Hold
1,850,000
– – 0.26% 74
2023
Q2 		$2.57M Hold
1,850,000
– – 0.38% 63
2023
Q1 		$2.94M Buy
+1,850,000
New +$9.55M 0.44% 56
2022
Q4 		– Sell
-500,000
Closed -$3.35M – 97
2022
Q3 		$3.35M Buy
+500,000
New +$3.43M 0.41% 54

Other funds holding ESPR

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Tang Capital Management's ESPR Position: Q1 2024 in Review

Tang Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 1,850,000 shares — an estimated $5.53M sold.

Tang Capital Management first reported a position in ESPR in Q3 2022 and held it in 5 quarters. The position peaked at $5.53M in Q4 2023. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

  • Tang Capital Management reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 1,850,000 Esperion Therapeutics shares in Q1 2024, an estimated $5.53M.
  • Tang Capital Management first reported a position in Esperion Therapeutics in Q3 2022 and held it in 5 quarters.
  • Tang Capital Management's Esperion Therapeutics position peaked at $5.53M in Q4 2023.
  • 153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.